← Library
CJC-1295 (with DAC)
Research Use
Also known as CJC-1295 DAC, DAC-GHRH
Function
Primary
GH pulse amplification · IGF-1 elevation
Secondary
Body composition · Anti-aging
Mechanism
GHRH analog with C8 fatty-acid DAC modification — extends half-life to 6–8 days; stimulates pituitary GH release; raises IGF-1 chronically.
Evidence
Pre-clinical / Observational
Research
Phase I/II (Teichman 2006); no Phase III
Dosing
Range
1–2 mg/week
Frequency
Weekly or biweekly
Route
Subcutaneous
Administration & Technique
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
Device31G × 5/16" insulin syringe (U-100). 100 units = 1 mL.
TechniquePinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Injection & Application Sites
Front
Back
Subcutaneous (SubQ)
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
8–12 weeks on / 4 weeks off.
Timing & Interactions
When to take
Once weekly, any time of day. DAC extends half-life so pulse timing is less critical, but many users dose in the evening to align with the natural nocturnal GH surge. Avoid food (especially carbs/fats) for 2–3 hrs before if pulsing GH is a goal.
Do not combine with
- ·Other long-acting GHRH analogs (Tesamorelin, Sermorelin) — redundant and raises IGF-1 excessively
- ·MK-677 chronically — additive IGF-1 elevation, insulin resistance risk
- ·High-carb meals within 2 hrs of dosing — blunts GH pulse
Complements
- ·Ipamorelin (GHRP) — synergistic GH release via separate receptor
- ·BPC-157 / TB-500 — recovery amplification during GH cycles
Notes
Cycle 8–12 weeks on / 4 weeks off. Monitor fasting glucose & IGF-1.
Storage & Reconstitution
Powder (Pre-Reconstitution)
Lyophilized powder: refrigerate 2–8°C for up to 24 months, or freeze at –20°C for extended storage. Keep sealed, desiccated, and protected from light.
After Reconstitution
After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Discard if cloudy, discolored, or precipitated.
Notes
Do not freeze after reconstitution — freeze/thaw cycles degrade most peptides.
Reconstitution Calculator
Concentration
2.50 mg/mL
Volume per dose
0.100 mL
Insulin syringe
10.0 units (U-100)
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Your Notes
Sign in to save personal notes on CJC-1295 (with DAC) and sync them to Vial Lab.
Benefits
- ·Sustained GH/IGF-1 elevation
- ·Convenient weekly dosing
- ·Improved body composition (anecdotal)
Risks
- ·Loss of GH pulsatility
- ·Water retention
- ·Tingling/numbness
- ·Elevated IGF-1 oncogenicity concern
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Severe diabetic retinopathy
Regulatory
Not FDA-approved; compounded/research use
Veterinary Use (Pets)
Occasional use in performance horses and canine agility athletes for GH-axis support.
Dogs (Canine)
Dose0.5–1 mcg/kg weekly
RouteSubQ
UseBody composition, recovery.
Horses (Equine)
Dose500–1000 mcg per horse weekly
RouteSubQ
UseGH-axis support in aged performance horses.
Prohibited in competition; extremely long half-life makes withdrawal impractical.
Functional Groups
Cited Works
- Teichman SL et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91:799.source